Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 7/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 7/20 | 0.94 |
| ▸ | MAPK7 | Q13164 | 12/20 | 0.90 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.84 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.67 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.67 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596956 | 1.00 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL29389108 | 1.00 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616960 | 0.95 | LRRK2 (0.90) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616339 | 0.95 | MAPK7 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16065732 | 0.94 | MAPK7 (0.89) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL619716 | 0.93 | NUAK1 (0.95) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL17465882 | 0.93 | MAPK7 (0.88) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16065728 | 0.92 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16065723 | 0.92 | LRRK2 (0.86) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL18371570 | 0.92 | LRRK2 (0.86) | LRRK2BRD4BRDTDCLK1MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100063-A1 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | HOFFMANN-LA ROCHE INC. (US) | 2024-03-28 | — | — | US | claimed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| US-20240100063-A1 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | HOFFMANN-LA ROCHE INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20210230538-A1 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-07-29 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2015196072-A2 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015176010-A1 | TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENTOF HEALTH & HUMAN SERVICES (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015117087-A1 | USES OF DIAZEPANE DERIVATIVES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015117083-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | LRRK2 364/4885BRD4 555/4885BRDT 783/4885 |
| US-20240100063-A1 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | LRRK2, PDCD1, CD274 | LRRK2 1/4885BRD4 68/4885BRDT 259/4885 |
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, PINK1 | LRRK2 1/4885BRD4 1849/4885BRDT 3045/4885 |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | LRRK2 1/4885BRD4 3044/4885BRDT 3481/4885 |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | LRRK2 1/4885BRD4 3044/4885BRDT 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.